• Title of article

    Randomised double-blind placebo-controlled study of the effect of inhibition of nitric oxide synthesis in bradykinin-induced asthma

  • Author/Authors

    Fabio LM Ricciardolo، نويسنده , , Pierangelo Geppetti، نويسنده , , Antonino Mistretta، نويسنده , , Jay A Nadel، نويسنده , , Maria A Sapienza، نويسنده , , Salvatore Bellofiore، نويسنده , , Giuseppe U Di Maria، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 1996
  • Pages
    4
  • From page
    374
  • To page
    377
  • Abstract
    Background Bronchoconstriction induced by bradykinin is reduced by the release of nitric oxide (NO) in the airways of guineapigs. Inhaled NO is known to cause broncho-dilatation in asthmatic patients. To find out the role of endogenous NO in airway response to bradykinin in asthma, we examined the effect of the NO synthase inhibitor NG-monomethyl-L-arginine (L-NMMA) on bronchoconstriction after bradykinin challenge in ten patients with mild asthma. Methods The study had a randomised, double-blind, placebo-controlled, cross-over design. Participants were studied during two phases, each consisting of 2 study days. After baseline measurements of forced expiratory volume in 1 s (FEV1) participants inhaled an aerosol of L-NMMA or saline (placebo). After 5 min, saline and doubling doses of bradykinin (from 0·25 nmol) were inhaled until FEV1 fell by at least 20% of the post-saline value. The effect of L-NMMA and placebo on airway response to doubling concentrations of methacholine (from 0·03 mg/mL) was then examined. We also assessed the effect of the inactive enantiomer of L-NMMA, D-NMMA, and placebo on bronchoconstriction after bradykinin or methacholine challenge in six of the participants. Findings The geometric mean of the provocative dose producing a 20% fall in FEV1 to bradykinin was 138·0 nmol (range 48·2-475·2 nmol) after placebo and 11·2 nmol (range 0·9-51·3 nmol) after L-NMMA (p < 0·01). L-NMMA also caused a decrease in the provocative concentration of methacholine producing a 20% fall in FEV1 from 0·93 mg/mL (range 0·12-2·55 mg/mL) to 0·38 mg/mL (range 0·06-0·92 mg/mL; p < 0· 01). In contrast, D-NMMA did not affect airway response to bradykinin or methacholine. Interpretation The results suggest that bronchoconstriction after bradykinin inhalation is greatly inhibited by the formation of NO in airways of asthmatic patients and that NO could have a bronchoprotective role in asthma.
  • Journal title
    The Lancet
  • Serial Year
    1996
  • Journal title
    The Lancet
  • Record number

    571090